Rare Oral Mucosal Manifestations of Hydroxyurea Therapy in Chronic Myeloid Leukemia

Authors:

Deena Mudawi*, Abdulqadir J Nashwan, Amna Gameel, Shehab Fareed, Mohammad Abdulla and Mohamed A Yassin*

DOI: 10.23880/hij-16000107

Volume 1, Issue 2

Abstract

Chronic myeloid leukemia (CML), is myeloproliferative neoplasm, that accounts for 15-20% of all leukemia’s in adults, resulting from reciprocal translocation between the long arms of chromosomes 9 and 22(Philadelphia chromosome), producing BCR-ABL oncogene fusion, which is currently targeted by tyrosine kinase inhibiters (TKIs), but still Hydroxyurea (HU) usedin chronic myeloid leukemia, its role as cytoreduction and as bridging therapy before starting tyrosine kinase inhibitors (TKI). There are several recognized side effects of hydroxyurea, such as cutaneous abnormalities and here we report rare mucous manifestations of hydroxyurea.

Keywords:

Rare oral mucosal; Chronic myeloid leukemia; Hydroxyurea

View PDF